Tristar Wellness Solutions, Inc. (TWSI)

[sweet crude]

Q3 earnings coming

i see a lot of other medical companies with zero revenue, and year or more away from FDA approval...we have both.

Could see buyers lift this near .30+ going into earnings in November...float super thin so who knows what or where this could go.

[VisionTrade]

TriStar Wellness (TWSI) Receives Funding for Prostate Cancer Surgical Product

Last Updated: October 13, 2015 8:00 AM EST


(NEW YORK)--TriStar Wellness Solutions, Inc. (OTC:TWSI), a health and wellness company that targets opportunities in the advanced wound care marketplace, receives Phase II funding from NIH for prostate cancer surgical product.

TWSI wholly owned subsidiary, HemCon Medical Technologies, Inc., was awarded $1.1 million in funding from the National Institutes of Health (NIH) to develop a novel chitosan endoluminal hemostatic dressing that is able to be delivered by a catheter to control and prevent prostatic bleeding during prostatic surgery such as transurethral resection of the prostate (TURP).

Oregon Health & Science University (OHSU) will work with TWSI as a subcontractor in development of the dressing.

Prostate benign hyperplasia (BPH) and prostate cancer are two of the most common urologic diseases that are treated with surgical intervention in older men. The Department of Health and Human Services report approximately 150,000 prostatic surgical procedures performed in the U.S. annually. Uncontrolled bleeding associated with transurethral and open prostatic surgical procedures often results in delayed healing, increased patient discomfort and ultimately prolonged hospitalization which significantly increases the cost of patient care.
The chitosan endoluminal hemostatic dressing development will enable rapid control of bleeding, reduce discomfort associated with extended catheterization, and more significantly enable reduction in hospital stays and expenditure. A previous Phase I award demonstrated feasibility of the chitosan endoluminal hemostatic dressing, its incorporation into a urinary catheter device, and its use to control bleeding in a large animal model. The Phase II funding that has now been awarded provides for development of a final balloon-delivered hemostatic system.

TriStar Wellness Solutions, Inc. produces a line of FDA approved hemostatic blood control products approved in both the US, and China. For the first six months of 2015 the Company reported total sales revenues of $1.9 million, and is expected to report third quarter sales results in mid-November.

TWSI currently has around 27 million shares issued and outstanding, and trades on the OTCQB exchange under the stock symbol "TWSI".

[sweet crude]

First China sales should be in Q2

Im not expecting anything major, but i think this quarter should show first sales in China on top line. Any new sources of revenue and we start to see this going.

With stock moving towards turning an actual profit, and trading below .30, this thing should start drawing in new eyes...a profitable company is rare in penny land...gonna post that article around cause its a great eye catcher

TWSI

[sweet crude]

Looking for sharp Net Loss decrease

If they can show even half way decent revenues, with the new gross margins in place, we could see TWSI start to show signs it might turn a profit. i think that is exactly what will start to draw in eyes cause been shocked how this has just been ignored....of course company should put out more updates, and emailed their IR to get them on that.

If they show a net profit for Q2 look out...blast off time, but think we may still be another quarter away for that, but looking forward to 10Q

TWSI

[Penny Nickel Dine]

TWSI Making Move Towards Profitability
By: staff reporter, John Bodger
Last Updated: August 17, 2015 1:45 PM EST

(NEW YORK)--TriStar Welness Solutions, Inc. (OTC:TWSI), a health and wellness company, may be moving towards profitability as their gross margins are indicated to show continued improvement.

In a 10Q-NT filing late Friday TWSI indicated they would show increased gross margins based on their out sourcing manufacturing of their HemCon products to a third party. This has had the effect in decreasing TWSI's net loss dramatically, and may be setting the stage for the company to post a profit this year,

TWSI cost of goods sold for the three months ended March 31, 2015 was $398,000, compared to $1,038,000 for the same period in 2014. The Company's gross margins increased significantly for the three months ended March 31, 2015 compared to March 31, 2014, primarily due to their transition from in-house manufacturing of their HemCon products to utilizing outsourced, third-party manufacturers. This transition began in December 2014.

Based on these improved gross margins TWSI operating loss decrease nearly 50% to approximately ($583,000) for the three months ended March 31, 2015, compared to an operating loss of ($1,207,000) for the three months ended March 31, 2014.

Based on these increased gross margins, and rapidly decreasing net loss, TWSI may be on path to potentially become profitable sometime in fiscal 2015.

To get an idea of the possible interest in this sector one can look at Arch Theraputices, Inc. (OTC:ARTH), which recently say its stock rally from $0.20 to near $0.40 on very high volume. ARTH is another hemostatic company that is pre-clinical trials, where as TWSI current holds both FDA and CFDA approval in the US and China.

TWSI currently has around 25 million shares issued and outstanding, and was last traded around $0.13 per share. http://www.otcmarkets.com/stock/twsi/quote

About TriStar Wellness Solutions, Inc.

TriStar Wellness Solutions (OTC:TWSI) is a health and wellness company that targets under-met consumer opportunities in the OTC and professional marketplace. Its core strategy plans to meet the growing demand for personalized, care solutions by leveraging proprietary innovation and healthcare technology with the rapid transformation of the healthcare marketplace to create innovative, science based solutions and brands. TriStar recently acquired HemCon Medical Technologies Inc., a developer, manufacturer, and marketer of innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. It also owns the Beauty de MamanTM brand of women's health products. Additional information is available at www.tstarwellness.com

http://wallstreetnewscast.com/news/2015/08/twsi-5209.html

[VisionTrade]

HemCon Medical with the positive financials about to be released will move "TWSI" way pass a 1.00. Huge factor is the super low float. It will take one day with volume to push "TWSI" over a 1.00.

[Penny Nickel Dine]

ARTH been on fire, is TWSI next?

ARTH has been going nuts and from what i get they are still only in pre-clinical studies, where as TWSI already has FDA approval. If TWSI could score just a fraction of ARTH retail volume this thing could explode.

Look at ARTH and TWSI chart...radaring TWSI as possible next flare up in this sector.

[sweet crude]

Higher gross margins = going profitable!!!

...all depends how much more net loss decreased, but at this pace TWSI go profitable this yeat...KABOOM!!!

[Stock Rockstar]

TWSI projecting higher gross margins...MAJOR!!!

This was from 10Q-NT filed. With higher gross margins then we could see some stronger earnings going forward from here. this is what was said in 10Q-NT

We anticipate our financial results for the three and six months ended June 30, 2015, will differ significantly from the prior year due to our transition from in-house manufacturing of our HemCon products to utilizing outsourced, third-party manufacturers. This transition began in December 2014. We believe this move will result in a significantly increased gross margin ratio for the products we sold during the three and six months ended June 30, 2015 compared to those sold during the three and six months ended June 30, 2014. The exact impact of these changes will not be known until our financial statements for the periods ended June 30, 2015 are completed.

This could finally start TWSI up to life!

[sweet crude]

TWSI has both FDA and CFDA approval

TWSI has approval with FDA and FDA in China..that alone should send this stock in flurry. Next 10Q expected, lets see what they did in Q2 revenue wise.

CEO only holds warrants with strike price for $1.00...he dont get paid until TWSI gets above $1.00, that's a big bullish sign.

Float super thin....lets set this puppy off to moon

TWSI

[sweet crude]

ask .18

http://www.otcmarkets.com/stock/TWSI/quote

thin up into .30s

[Penny Nickel Dine]

TWSI is WAY better than ARTH!

KABOOM!

[Penny Nickel Dine]

Hey Vision what do you expect for upcoming earnings?

[Penny Nickel Dine]

The CEO has warrants at $1 dollar?

[sweet crude]

ARTH been on fire, TWSI should as well

ARTH still in pre-clinical trials, TWSI already has FDA approval. We need update from company...i sent email in lets see what happens into earnings in mid August

TWSI

[Penny Nickel Dine]

This has potential to run to $1.00!

I already follow ARTH but this stock already has FDA approval... KABOOM!

[VisionTrade]

TWSI
Outstanding Shares: 25.17M
Float: 7.65M

Note: the above low numbers will move this stock fast with volume.

[VisionTrade]

"TWSI" has been moved up to a 96% buy rating by barchart.com. Plus, the stock float is 7.65M, which is super low, meaning it will not take much action to move "TWSI" into the multi-dollar range.

[sweet crude]

Weekly chart looking bullish

[VisionTrade]

Ready for a strong movement up in the multiple dollar range. HemCon Medical a subsidiary of "TWSI" is under going tremendous growth.

[sweet crude]

Golden cross on chart

[Stock Rockstar]

TWSI funding for phase II...chart breaking out

Funding for phase II prostate cancer product from NIH, has FDA approval in both US and China

Chart breaking out!

[sweet crude]

China sales already underway

Chart holding steady and any smack on .28 ask and things swing bullish. Could easily see $1.00+

TWSI

[VisionTrade]

More updated positive news on the way, but company is unable to disclose at this time.

[Stock Rockstar]

Yes, it's definitely undervalued and due to run soon imo

[sweet crude]

Ask .28

Level 2 Ask = .28, .30, then .32
http://www.otcmarkets.com/stock/twsi/quote

[VisionTrade]

Revenues starting to come in on China deals. "TWSI" is about to explode up the chart.

[Spydermelee]

2.00 Dec

[VisionTrade]

We need a good promo and positive financial update to move this stock up above 1.00$.

[Stock Rockstar]

$TWSI looking great. $.40 in no time, imo!

[sweet crude]

China sales should be big

sales in China have already started. id love to get an update on that front, but that should help boast top line revenues sales, expect big jump in coming next two quarters....could make run to $1.00+ during summer time

TWSI

[VisionTrade]

CEO needs to have "TWSI" above 1.00$ a share to be able sell some of his shares. We are about to see a major up trend on the share price.

[VisionTrade]

Barcharts.com has "TWSI" as a 64% strong buy rating.

Outstanding Shares: 24M
Float: 9M
Above Means: Able to move stock price up the chart fast.

Deals with China and millions in funding. Strong growth is written all over "TWSI".

[sweet crude]

1 MM left @ .32

http://www.otcmarkets.com/stock/TWSI/quote

TWSI

[sweet crude]

ask .32 ($1.00+ coming)

http://www.otcmarkets.com/stock/TWSI/quote

TWSI

[VisionTrade]

Bounce time!! "TWSI" is going to see a very run up the chart. Major news.

[sweet crude]

Major chart breakout...next stop $1.00

If things hold up well and TWSI doesnt do anything dum, this could run to $1.00+

Remember, the CEO gets no salary, has no stock, but does have 550,000 warrants with strike price of $1.00.....so he doesnt make any money unless TWSI goes to, and above $1.00

Buy at will...gonna be a interesting summer

TWSI major breakout...running (see chart)

25 million outstanding
Float 9 million

[VisionTrade]

TWSI gets Phase 2 Funding for Prostate Cancer Product from NIH
By: staff reporter, John Bodger
Last Updated: May 21, 2015 8:43 AM EST

(NEW YORK)--TriStar Wellness Solutions, Inc. (OTC:TWSI), a health and wellness company that targets opportunities in the advanced wound care marketplace, announced that its wholly owned subsidiary HemCon Medical Technologies, Inc. was awarded funding from the National Institutes of Health (NIH) of $1.1 million to develop a novel chitosan endoluminal hemostatic dressing that is able to be delivered by a catheter to control and prevent prostatic bleeding during prostatic surgery such as transurethral resection of the prostate (TURP).

Oregon Health & Science University (OHSU) will work with HemCon as a subcontractor in development of the dressing.

Prostate benign hyperplasia (BPH) and prostate cancer are two of the most common urologic diseases that are treated with surgical intervention in older men. The Department of Health and Human Services report approximately 150,000 prostatic surgical procedures performed in the U.S. annually. Uncontrolled bleeding associated with transurethral and open prostatic surgical procedures often results in delayed healing, increased patient discomfort and ultimately prolonged hospitalization which significantly increases the cost of patient care.
The chitosan endoluminal hemostatic dressing development will enable rapid control of bleeding, reduce discomfort associated with extended catheterization, and more significantly enable reduction in hospital stays and expenditure. A previous Phase I award demonstrated feasibility of the chitosan endoluminal hemostatic dressing, its incorporation into a urinary catheter device, and its use to control bleeding in a large animal model. The Phase II funding that has now been awarded provides for development of a final balloon-delivered hemostatic system.

China FDA Approval

In addition to this product, TWSI recently announced approval from the China Food and Drug Administration (CFDA) to market and sell their line of medical products into China. TWSI has commercially entered the market as of April 2015 by accepting an order through a distributor on the mainland, and will include its full portfolio of wound care solutions which are protected by patents both in China and throughout the world. Currently the wound care market in China is estimated at $1.2 billion. TWSI now current holds FDA approval in both the US and China.

[VisionTrade]

Float: 8.75 Million

[Skipman6]

Does anyone know what the float on this is?

[Global Source]

Wow!! TWSI does have amazing numbers tied to it.

Enterprise Value: 12.01M
Float: Only 8.75M (Stock will move fast)

I see lots of growth for TWSI because of HenCom Medical and it's dealings with China and new funding.

[VisionTrade]

I have be saying for days that there is a run coming. It now has started. This run will be major.

[VisionTrade]

We are about to see a nice run update the chart with all the great news being posted on "TWSI"!!!

[sweet crude]

.175 x .245

chart breaking out...only 3000 shares left @ .245
http://www.otcmarkets.com/stock/twsi/quote

TWSI

[Global Source]

Prefect news today on all fronts!!! Second round of funding for HemCon Medical, plus China deals is going to move "TWSI" fast.

"TWSI" will see major gains.

[sweet crude]

TWSI gets Phase 2 Funding from NIH

TWSI gets Phase 2 Funding for Prostate Cancer Product from NIH

(NEW YORK)--TriStar Wellness Solutions, Inc. (OTC:TWSI), a health and wellness company that targets opportunities in the advanced wound care marketplace, announced that its wholly owned subsidiary HemCon Medical Technologies, Inc. was awarded funding from the National Institutes of Health (NIH) of $1.1 million to develop a novel chitosan endoluminal hemostatic dressing that is able to be delivered by a catheter to control and prevent prostatic bleeding during prostatic surgery such as transurethral resection of the prostate (TURP).

Oregon Health & Science University (OHSU) will work with HemCon as a subcontractor in development of the dressing.

Prostate benign hyperplasia (BPH) and prostate cancer are two of the most common urologic diseases that are treated with surgical intervention in older men. The Department of Health and Human Services report approximately 150,000 prostatic surgical procedures performed in the U.S. annually. Uncontrolled bleeding associated with transurethral and open prostatic surgical procedures often results in delayed healing, increased patient discomfort and ultimately prolonged hospitalization which significantly increases the cost of patient care.
The chitosan endoluminal hemostatic dressing development will enable rapid control of bleeding, reduce discomfort associated with extended catheterization, and more significantly enable reduction in hospital stays and expenditure. A previous Phase I award demonstrated feasibility of the chitosan endoluminal hemostatic dressing, its incorporation into a urinary catheter device, and its use to control bleeding in a large animal model. The Phase II funding that has now been awarded provides for development of a final balloon-delivered hemostatic system.

China FDA Approval

In addition to this product, TWSI recently announced approval from the China Food and Drug Administration (CFDA) to market and sell their line of medical products into China. TWSI has commercially entered the market as of April 2015 by accepting an order through a distributor on the mainland, and will include its full portfolio of wound care solutions which are protected by patents both in China and throughout the world. Currently the wound care market in China is estimated at $1.2 billion. TWSI now current holds FDA approval in both the US and China.

TWSI currently has around 25 million shares issued and outstanding, and was last traded around $0.20 per share.
http://www.wallstreetnewscast.com/news/2015/05/twsi-nih-1285.html


SRPT PBMD ONTY INVT ARTH UEEC

[sweet crude]

.25 BREAKOUT!!!

TWSI

[VisionTrade]

NEWS!!! is out to send "TWSI" into orbit. This second phase of funding is massive for the future of HemCom Medical witch is a subsidiary of "TWSI". I see a 1.00 per share being a steal with this news. "TWSI" will see closer to 5.00 a share in short time.

Note: Super low float on "TWSI"

[Stock Rockstar]

Great find! GM to all. Let's go $TWSI!!

[VisionTrade]

TWSI gets Phase 2 Funding for Prostate Cancer Product from NIH
By: staff reporter, John Bodger
Last Updated: May 21, 2015 8:43 AM EST

(NEW YORK)--TriStar Wellness Solutions, Inc. (OTC:TWSI), a health and wellness company that targets opportunities in the advanced wound care marketplace, announced that its wholly owned subsidiary HemCon Medical Technologies, Inc. was awarded funding from the National Institutes of Health (NIH) of $1.1 million to develop a novel chitosan endoluminal hemostatic dressing that is able to be delivered by a catheter to control and prevent prostatic bleeding during prostatic surgery such as transurethral resection of the prostate (TURP).

Oregon Health & Science University (OHSU) will work with HemCon as a subcontractor in development of the dressing.

Prostate benign hyperplasia (BPH) and prostate cancer are two of the most common urologic diseases that are treated with surgical intervention in older men. The Department of Health and Human Services report approximately 150,000 prostatic surgical procedures performed in the U.S. annually. Uncontrolled bleeding associated with transurethral and open prostatic surgical procedures often results in delayed healing, increased patient discomfort and ultimately prolonged hospitalization which significantly increases the cost of patient care.
The chitosan endoluminal hemostatic dressing development will enable rapid control of bleeding, reduce discomfort associated with extended catheterization, and more significantly enable reduction in hospital stays and expenditure. A previous Phase I award demonstrated feasibility of the chitosan endoluminal hemostatic dressing, its incorporation into a urinary catheter device, and its use to control bleeding in a large animal model. The Phase II funding that has now been awarded provides for development of a final balloon-delivered hemostatic system.

China FDA Approval

In addition to this product, TWSI recently announced approval from the China Food and Drug Administration (CFDA) to market and sell their line of medical products into China. TWSI has commercially entered the market as of April 2015 by accepting an order through a distributor on the mainland, and will include its full portfolio of wound care solutions which are protected by patents both in China and throughout the world. Currently the wound care market in China is estimated at $1.2 billion. TWSI now current holds FDA approval in both the US and China.

TWSI currently has around 25 million shares issued and outstanding, and was last traded around $0.20 per share.

About TriStar Wellness Solution, Inc.

TriStar Wellness Solutions, Inc. is a health and wellness company that targets under-met consumer opportunities in the OTC and professional marketplace. Its core strategy plans to meet the growing demand for personalized, care solutions by leveraging proprietary innovation and healthcare technology with the rapid transformation of the healthcare marketplace to create innovative, science based solutions and brands. TriStar recently acquired HemCon Medical Technologies Inc., a developer, manufacturer, and marketer of innovative technologies for hemostatic devices for the control of bleeding resulting from trauma or surgery. It also owns the Beauty de MamanTM brand of women's health products. Additional information is available at www.tstarwellness.com